Mumbai: No Relief For Wholesalers Who Sold Fake Covid-19 Medicine

Mumbai : A sessions court in Dindoshi on Friday rejected anticipatory bail pleas of two drug wholesalers booked by the Vanrai and Samta Nagar police stations for stocking spurious Favimax 400 drug, widely used in the treatment of Covid-19 infection.

On 24 May, upon a tip-off, the Food and Drug Administration (FDA) raided three wholesalers in the suburbs of Kandivali and Goregaon areas. In Kandivali, it found fake drug worth Rs 21 lakh and in Goregaon Rs 1 crore. Accordingly, Samta Nagar police station had booked wholesaler Nilesh Khimani and Vanrai police booked Manjiri Kadam by Vanrai police for the offences of cheating, forgery and under provisions of the Drugs and Cosmetics Act.

Both had approached the court apprehending arrest and claimed in their pleas that they did not have the knowledge that the drugs were not genuine, that they were only sellers and had no role in the offence.

Additional Public Prosecutor Sachin Jadhav had opposed grant of relief to them and told the court that the duo procured the fake drug, having knowledge that they are not genuine, from the main accused Sudeep Mukherjee, the owner of Max Relief Healthcare in Himachal Pradesh. Probe by the FDA had found that the company did not exist, but its ‘owner’ Mukherjee sold the fake drugs manufactured by a pharma lab employee in Uttar Pradesh, whom another person helped package it. Prosecutor Jadhav further pointed out that it was only a profiteering motive during a pandemic, with which the duo purchased a huge stock of the fake drug. Their custodial interrogation was required, he told the court, to find where they had sold the spurious drug. Additional Sessions Judge SU Baghele rejected relief to the duo.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’